Sana Biotechnology aims to raise $150M in IPO

Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. The preclinical biotech is looking to raise up to $150 million on the Nasdaq under the symbol SANA. The gene therapy company, which was co-founded in July 2018 by former Juno Therapeutics Chief Financial Officer Steve Harr, announced last year it had raised more than $700 million in venture capit al. It has grown from 37 full-time employees in December 2018 to…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news